<DOC>
	<DOCNO>NCT00954798</DOCNO>
	<brief_summary>The purpose study generate data immunogenicity safety monovalent H1N1 vaccine support development registration . Primary objective : - To describe immune response study vaccine 21 day vaccination . - To describe antibody persistence 8 month first vaccine administration use hemagglutination inhibition ( HAI ) method randomize subset adult subject receive two injection . - To describe immune response A/H1N1 strain use HAI method 21 day vaccination 2010-2011 Northern Hemisphere ( NH ) seasonal trivalent influenza vaccine ( TIV ) administer 13 month first vaccination subset subject receive A/H1N1 influenza vaccine subject naïve swine origin A/H1N1 strain . - To describe safety profile study vaccine participant .</brief_summary>
	<brief_title>A Study Swine-origin A/H1N1 Influenza Vaccines Healthy European Adults Elderly</brief_title>
	<detailed_description>All participant receive two injection randomized vaccine Day 0 Day 21 , respectively . A subset participant receive third vaccine injection ( 2010-2011 Northern Hemisphere [ NH ] seasonal trivalent influenza vaccine [ TIV ] ) approximately 13 month first vaccination ; additionally , subset participant ' naïve swine-origin A/H1N1 strain also receive one vaccine injection 2010-2011 NH seasonal TIV .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria : Aged 18 year day inclusion Informed Consent Form sign date Able attend schedule visit comply trial procedure For woman childbearing potential , use effective method contraception abstinence least 4 week prior first vaccination least 4 week last vaccination Entitled national social security At Visit 05 , antibody persistence assessment : Addendum 1 Informed Consent Form sign dated Having receive two vaccination vaccine formulation 1 2 . At Month 13 , trivalent influenza vaccine ( TIV ) administration subject receive A/H1N1 influenza vaccine : Addendum 2 Informed Consent Form sign date Exclusion Criteria : Known pregnancy , positive urine pregnancy test Currently breastfeed child Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede first trial vaccination Planned participation another clinical trial present trial period Receipt vaccine 4 week precede first trial vaccination Planned receipt vaccine prior Day 42 blood sample Receipt blood bloodderived product past 3 month , might interfere assessment immune response Known suspect congenital acquired immunodeficiency ; receipt immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month ; longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week within past 3 month ) Selfreported seropositivity Human Immunodeficiency Virus ( HIV ) , Hepatitis B , Hepatitis C Known systemic hypersensitivity vaccine component , history lifethreatening reaction vaccine ( ) use trial vaccine contain substance Selfreported thrombocytopenia , contraindicate intramuscular ( IM ) vaccination Bleeding disorder , receipt anticoagulant 3 week precede inclusion , contraindicate IM vaccination Deprived freedom administrative court order , emergency setting , hospitalize involuntarily Current alcohol abuse drug addiction might interfere ability comply trial procedure Chronic illness , opinion Investigator , stage might interfere trial conduct completion Employee Investigator study center , direct involvement propose study study direction Investigator study center , well family member employee Investigator Previous participation trial investigate vaccine swineorigin A/H1N1 influenza strain Confirmed infection swineorigin A/H1N1 influenza strain ( different seasonal strain ) 2009 Febrile illness ( temperature ≥ 38.0°C ) moderate severe acute illness/infection day vaccination , accord Investigator judgment Receipt allergy shot and/or seasonal allergy medication 7day period prior enrollment ( vaccination ) , schedule receive allergy shot and/or seasonal allergy medication 7day period enrollment ( vaccination ) At Month 8 , antibody persistence assessment : Subjects receive , context pandemic immunization program , another A/H1N1 pandemic influenza vaccine Investigational Medicinal Products . Additional criterion subset receive TIV : History pandemic A/H1N1 influenza vaccination History clinically laboratory confirm pandemic A/H1N1 influenza infection Receipt adjuvanted influenza vaccine clinical trial within previous 12 month Planned receipt vaccine present trial period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Pandemic Flu</keyword>
	<keyword>Swine-origin Influenza</keyword>
	<keyword>Inactivated split-virion vaccine</keyword>
	<keyword>Adjuvant</keyword>
	<keyword>Adult</keyword>
</DOC>